The m6A demethylase FTO targets POLQ to promote ccRCC cell proliferation and genome stability maintenance

Abstract

Background and aim As the first identified m6A demethylase, FTO has been implicated in the progression of various cancers. However, the specific mechanism of FTO in clear cell renal cell carcinoma (ccRCC) remains incompletely understood. In this study, we aimed to explore the potential molecular mechanisms influencing the progression of ccRCC. Methods We initially assessed the expression of FTO in tumor and adjacent tissues using TCGA database, RT-qPCR, and Western blot. We then conducted CCK-8, cell cycle analysis, and colony formation assay to investigate the impact of FTO on ccRCC cell proliferation. MeRIP-seq and RNA-seq were employed to identify potential downstream targets of FTO in ccRCC, and these findings were further validated through dual-luciferase reporter assays and MeRIP-qPCR. Then, DNA damage and cell death were assessed separately through gammaH2AX immunofluorescence detection and the LIVE/DEAD Fixable Dead Cell Stain assay, respectively. Subsequently, we identified downstream pathways influenced by FTO's regulation of POLQ through TCGA database analysis and GSEA enrichment analysis. Validation was carried out through Western blot. Results FTO is highly expressed in ccRCC tissues and cell lines. Furthermore, ROC curve demonstrates that FTO contributes to the diagnosis of ccRCC. FTO modulates m6A modification, consequently influencing the expression of POLQ, thus facilitating cell proliferation and maintaining genome stability in ccRCC. Conclusion FTO could potentially serve as a diagnostic marker for ccRCC. FTO promotes the progression of ccRCC by regulating m6A modification, making the inhibition of FTO a potential novel therapeutic strategy in ccRCC.

Decoding the ribosome's hidden language: rRNA modifications as key players in cancer dynamics and targeted therapies

“…127 The dysregulation of rRNA modifications, along with the aberrant expression of various enzymes involved in these modifications (referred to as writers, erasers, and readers), is linked to poor prognosis, therapy resistance, and impaired anti-tumour immunity in various types of cancer. 128 As a result, the analysis of rRNA modification patterns, the enzymes that modify them, and the specific modification sites holds potential as diagnostic, prognostic, and predictive biomarkers. However, in practical clinical settings, it has been noted that RNA modifying enzymes can show similar patterns of dysregulation across different cancer types, and in some cases, exhibit contrasting roles in different cancers.…”